PT2646557T - Método para expressão de arn celular - Google Patents
Método para expressão de arn celular Download PDFInfo
- Publication number
- PT2646557T PT2646557T PT117914473T PT11791447T PT2646557T PT 2646557 T PT2646557 T PT 2646557T PT 117914473 T PT117914473 T PT 117914473T PT 11791447 T PT11791447 T PT 11791447T PT 2646557 T PT2646557 T PT 2646557T
- Authority
- PT
- Portugal
- Prior art keywords
- cells
- pkr
- rna
- stem cell
- fibroblasts
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims 14
- 108091092328 cellular RNA Proteins 0.000 title 1
- 210000004027 cell Anatomy 0.000 claims 14
- 102100034170 Interferon-induced, double-stranded RNA-activated protein kinase Human genes 0.000 claims 9
- 210000002950 fibroblast Anatomy 0.000 claims 5
- 239000003112 inhibitor Substances 0.000 claims 5
- 210000000130 stem cell Anatomy 0.000 claims 5
- 210000001082 somatic cell Anatomy 0.000 claims 4
- 230000000694 effects Effects 0.000 claims 3
- MWBWWFOAEOYUST-UHFFFAOYSA-N 2-aminopurine Chemical compound NC1=NC=C2N=CNC2=N1 MWBWWFOAEOYUST-UHFFFAOYSA-N 0.000 claims 1
- VFBGXTUGODTSPK-UHFFFAOYSA-N 8-(1h-imidazol-5-ylmethylidene)-6h-pyrrolo[2,3-g][1,3]benzothiazol-7-one Chemical group O=C1NC2=CC=C3N=CSC3=C2C1=CC1=CN=CN1 VFBGXTUGODTSPK-UHFFFAOYSA-N 0.000 claims 1
- 102100039247 ETS-related transcription factor Elf-4 Human genes 0.000 claims 1
- 101000813135 Homo sapiens ETS-related transcription factor Elf-4 Proteins 0.000 claims 1
- 101000984042 Homo sapiens Protein lin-28 homolog A Proteins 0.000 claims 1
- 102100025460 Protein lin-28 homolog A Human genes 0.000 claims 1
- 241000700618 Vaccinia virus Species 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 230000035578 autophosphorylation Effects 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 230000018109 developmental process Effects 0.000 claims 1
- 230000004069 differentiation Effects 0.000 claims 1
- 102000010982 eIF-2 Kinase Human genes 0.000 claims 1
- 108010037623 eIF-2 Kinase Proteins 0.000 claims 1
- 230000002500 effect on skin Effects 0.000 claims 1
- 210000003953 foreskin Anatomy 0.000 claims 1
- 230000030279 gene silencing Effects 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 230000008672 reprogramming Effects 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/67—General methods for enhancing the expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/70—Enzymes
- C12N2501/72—Transferases [EC 2.]
- C12N2501/727—Kinases (EC 2.7.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Transplantation (AREA)
- Developmental Biology & Embryology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Enzymes And Modification Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Claims (12)
- REIVINDICAÇÕES1. Método para fornecer células que têm características de célula estaminal in vitro caracterizado por compreender as etapas de (i) reduzir a atividade da proteína quinase dependente de ARN (PKR) numa população de células que compreende células somáticas, (ii) introduzir ARN com capacidade para expressar um ou mais fatores que permitem a reprogramação das células somáticas para células que têm características de célula estaminal em pelo menos uma porção das células somáticas e (iii) permitir o desenvolvimento de células que têm características de célula estaminal.
- 2. Método, de acordo com a reivindicação 1, caracterizado por o um ou mais fatores compreenderem 0CT4 e S0X2.
- 3. Método, de acordo com a reivindicação 2, caracterizado por o um ou mais fatores compreenderem adicionalmente ELF4 e/ou c-MYC e/ou NANOG e/ou LIN28.
- 4. Método, de acordo com qualquer uma das reivindicações 1 a 3, caracterizado por a etapa de reduzir a atividade de PKR nas células resultar numa intensificação da estabilidade e/ou uma intensificação da expressão do ARN nas células.
- 5. Método, de acordo com a reivindicação 4, caracterizado por a intensificação da expressão do ARN nas células compreender um aumento no nivel de expressão e/ou um aumento na duração da expressão do ARN nas células.
- 6. Método, de acordo com qualquer uma das reivindicações 1 a 5, caracterizado por a etapa de reduzir a atividade de PKR nas células compreender tratar as células com pelo menos um inibidor de PKR ou silenciar a expressão do gene de PKR.
- 7. Método, de acordo com a reivindicação 6, caracterizado por o inibidor de PKR inibir a autof osf orilação de PKR induzida por ARN.
- 8. Método, de acordo com a reivindicação 6 ou 7, caracterizado por o inibidor de PKR ser um composto de imidazol-oxindol, 2-aminopurina ou um inibidor de PKR derivado de forma virai.
- 9. Método, de acordo com a reivindicação 8, caracterizado por o referido imidazol-oxindol ser 6,8-di-hidro-8-(1H-imidazol-5-ilmetileno)-7H-pirrolo[2,3—g]benzotiazol-7-ona e em que o referido inibidor de PKR derivado de forma virai é selecionado a partir do grupo que consiste em virus vaccinia E3 e/ou K3, ou seu ARN.
- 10. Método, de acordo com qualquer uma das reivindicações 1 a 9, caracterizado por as células somáticas serem fibroblastos.
- 11. Método, de acordo com a reivindicação 10, caracterizado por os referidos fibroblastos serem fibroblastos de pulmão, fibroblastos de prepúcio ou fibroblastos dérmicos.
- 12. Método para fornecer tipos de célula diferenciada caracterizado por compreender as etapas de (i) fornecer células que têm caracteristicas de célula estaminal com a utilização do método, conforme definido em qualquer uma das reivindicações 1 a 11, e (ii) cultivar as células que têm caracteristicas de célula estaminal sob condições que induzem ou direcionam a diferenciação parcial ou completa para um tipo de célula diferenciada. Lisboa,
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2010/007362 WO2012072096A1 (en) | 2010-12-03 | 2010-12-03 | Method for cellular rna expression |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT2646557T true PT2646557T (pt) | 2017-10-03 |
Family
ID=44202296
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT117914473T PT2646557T (pt) | 2010-12-03 | 2011-12-02 | Método para expressão de arn celular |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20140030808A1 (pt) |
| JP (2) | JP6131433B2 (pt) |
| AU (1) | AU2011335428B2 (pt) |
| CA (1) | CA2819522C (pt) |
| DK (1) | DK2646557T3 (pt) |
| ES (1) | ES2640875T3 (pt) |
| HU (1) | HUE034558T2 (pt) |
| LT (1) | LT2646557T (pt) |
| PT (1) | PT2646557T (pt) |
| WO (2) | WO2012072096A1 (pt) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2807552A1 (en) | 2010-08-06 | 2012-02-09 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| PT3590949T (pt) | 2010-10-01 | 2022-08-02 | Modernatx Inc | Ácidos ribonucleicos contendo n1-metilpseudouracilos e suas utilizações |
| ME02871B (me) * | 2010-12-03 | 2018-04-20 | Biontech Rna Pharmaceuticals Gmbh | Postupak za ćelijsku ekspresiju rnk |
| JP2014511687A (ja) | 2011-03-31 | 2014-05-19 | モデルナ セラピューティクス インコーポレイテッド | 工学操作された核酸の送達および製剤 |
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| KR20190099538A (ko) | 2011-10-03 | 2019-08-27 | 모더나 세라퓨틱스, 인코포레이티드 | 변형된 뉴클레오사이드, 뉴클레오타이드, 및 핵산, 및 이들의 용도 |
| SG11201402666WA (en) | 2011-12-16 | 2014-10-30 | Moderna Therapeutics Inc | Modified nucleoside, nucleotide, and nucleic acid compositions |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| US9878056B2 (en) | 2012-04-02 | 2018-01-30 | Modernatx, Inc. | Modified polynucleotides for the production of cosmetic proteins and peptides |
| US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| EP2847329A4 (en) | 2012-04-02 | 2016-08-10 | Moderna Therapeutics Inc | MODIFIED POLYNUCLEOTIDES FOR THE PREPARATION OF CYTOPLASMA AND CYTOSCELETTE PROTEINS |
| ES2676470T3 (es) | 2012-11-09 | 2018-07-19 | Biontech Rna Pharmaceuticals Gmbh | Método para la expresión de ARN en células |
| RS63237B1 (sr) | 2012-11-26 | 2022-06-30 | Modernatx Inc | Terminalno modifikovana rnk |
| US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
| EP3052106A4 (en) | 2013-09-30 | 2017-07-19 | ModernaTX, Inc. | Polynucleotides encoding immune modulating polypeptides |
| US10323076B2 (en) | 2013-10-03 | 2019-06-18 | Modernatx, Inc. | Polynucleotides encoding low density lipoprotein receptor |
| EP4501318A2 (en) | 2014-04-23 | 2025-02-05 | ModernaTX, Inc. | Nucleic acid vaccines |
| EP3750993B1 (en) * | 2014-07-11 | 2023-12-27 | Celgene Corporation | Methods of improving vector transduction efficiency into t lymphocytes |
| KR101668074B1 (ko) * | 2015-02-12 | 2016-10-21 | 전북대학교산학협력단 | Ｐｋｒ 저해제를 유효성분으로 포함하는 기관지 천식의 예방 또는 치료용 조성물 |
| EP3261605B2 (en) | 2015-02-26 | 2022-04-20 | SiO2 Medical Products, Inc. | Cycloolefin polymer container with a scratch resistant and anti-static coating |
| EP3405579A1 (en) | 2016-01-22 | 2018-11-28 | Modernatx, Inc. | Messenger ribonucleic acids for the production of intracellular binding polypeptides and methods of use thereof |
| US20190167811A1 (en) | 2016-04-13 | 2019-06-06 | Modernatx, Inc. | Lipid compositions and their uses for intratumoral polynucleotide delivery |
| HUE061077T2 (hu) | 2016-05-18 | 2023-05-28 | Modernatx Inc | Interleukin-12 (IL12) kódoló polinukleotidok és felhasználásuk |
| CA3027428A1 (en) * | 2016-06-14 | 2017-12-21 | Regents Of The University Of Minnesota | Genetically modified cells, tissues, and organs for treating disease |
| US12195788B2 (en) * | 2017-01-12 | 2025-01-14 | University Of Central Florida Research Foundation, Inc. | High-throughput and single nucleotide resolution techniques for the determination of RNA post-transcriptional modifications |
| WO2018231990A2 (en) | 2017-06-14 | 2018-12-20 | Modernatx, Inc. | Polynucleotides encoding methylmalonyl-coa mutase |
| AU2021252164A1 (en) | 2020-04-09 | 2022-12-15 | Finncure Oy | Mimetic nanoparticles for preventing the spreading and lowering the infection rate of novel coronaviruses |
| US12194157B2 (en) | 2020-04-09 | 2025-01-14 | Finncure Oy | Carrier for targeted delivery to a host |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6326466B1 (en) * | 1996-07-30 | 2001-12-04 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Double-stranded RNA dependent protein kinase derived peptides to promote proliferation of cells and tissues in a controlled manner |
| IL126757A0 (en) * | 1998-09-07 | 1999-08-17 | Yissum Res Dev Co | Regulation of gene expression through manipulation of mRNA splicing and its uses |
| DK1309726T4 (en) | 2000-03-30 | 2019-01-28 | Whitehead Inst Biomedical Res | RNA Sequence-Specific Mediators of RNA Interference |
| EP2072618A1 (en) * | 2007-12-14 | 2009-06-24 | Johannes Gutenberg-Universität Mainz | Use of RNA for reprogramming somatic cells |
| WO2010124143A1 (en) * | 2009-04-23 | 2010-10-28 | Nevada Cancer Institute | Reprogramming of somatic cells with purified proteins |
-
2010
- 2010-12-03 WO PCT/EP2010/007362 patent/WO2012072096A1/en active Application Filing
-
2011
- 2011-12-02 US US13/990,729 patent/US20140030808A1/en not_active Abandoned
- 2011-12-02 LT LTEP11791447.3T patent/LT2646557T/lt unknown
- 2011-12-02 CA CA2819522A patent/CA2819522C/en active Active
- 2011-12-02 DK DK11791447.3T patent/DK2646557T3/en active
- 2011-12-02 JP JP2013541252A patent/JP6131433B2/ja active Active
- 2011-12-02 PT PT117914473T patent/PT2646557T/pt unknown
- 2011-12-02 AU AU2011335428A patent/AU2011335428B2/en active Active
- 2011-12-02 ES ES11791447.3T patent/ES2640875T3/es active Active
- 2011-12-02 HU HUE11791447A patent/HUE034558T2/en unknown
- 2011-12-02 WO PCT/EP2011/006061 patent/WO2012072269A1/en active Application Filing
-
2016
- 2016-11-29 JP JP2016231065A patent/JP2017079749A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| LT2646557T (lt) | 2017-10-10 |
| CA2819522A1 (en) | 2012-06-07 |
| WO2012072269A1 (en) | 2012-06-07 |
| JP2013545469A (ja) | 2013-12-26 |
| CA2819522C (en) | 2019-07-16 |
| JP6131433B2 (ja) | 2017-05-24 |
| US20140030808A1 (en) | 2014-01-30 |
| JP2017079749A (ja) | 2017-05-18 |
| DK2646557T3 (en) | 2017-10-02 |
| HUE034558T2 (en) | 2018-02-28 |
| AU2011335428A1 (en) | 2013-05-30 |
| WO2012072096A1 (en) | 2012-06-07 |
| ES2640875T3 (es) | 2017-11-07 |
| AU2011335428B2 (en) | 2016-12-22 |
| WO2012072096A8 (en) | 2012-07-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT2646557T (pt) | Método para expressão de arn celular | |
| Xie et al. | Crucial roles of different RNA-binding hnRNP proteins in Stem Cells | |
| Wu et al. | Roles of miRNA‐1 and miRNA‐133 in the Proliferation and Differentiation of Myoblasts in Duck Skeletal Muscle | |
| BR112016009465A2 (pt) | Vírus herpes simplex oncolítico recombinante (ohsv), ácido nucleico o codificando, estoque viral e composição o compreendendo, bem como seu uso | |
| US20160199419A1 (en) | Biomolecular group related to cell anti-aging | |
| Liu et al. | Epigenetic silencing of HDAC1 by miR-449a upregulates Runx2 and promotes osteoblast differentiation | |
| Hsueh et al. | STAT3 regulates the proliferation and differentiation of rabbit limbal epithelial cells via a ΔNp63-dependent mechanism | |
| Bader et al. | The therapeutic potential of microRNAs | |
| Skapek et al. | Regulation of cell lineage specification by the retinoblastoma tumor suppressor | |
| CN106244593B (zh) | 一种调节鹿茸茸皮快速生长的microRNA及其应用 | |
| FU et al. | Establishment of a miR? 31 transgenic mouse and its expression in tissues and organs | |
| CN104800860A (zh) | miR-17-92基因簇促进神经细胞增殖和神经再生的新应用 | |
| Yuan et al. | Inhibition of microRNA-182 reduces hypoxia/re-oxygenation-induced HL-1 cardiomyocyte apoptosis by targeting the nuclear respiratory factor-1/mitochondrial transcription factor A (NRF-1/mtTFA) pathway | |
| Delaloy et al. | A new role for microRNA-9 in human neural progenitor cells | |
| Park et al. | Genetic and Chemical Controls of Sperm Fate and Spermatocyte Dedifferentiation in Caenorhabditis elegans | |
| HRP20171393T1 (hr) | Postupak za staničnu ekspresiju rnk | |
| Thumiah-Mootoo | The Role of Mitophagy in Muscle Stem Cell Fate and Function During Muscle Regeneration | |
| Jiang et al. | Sodium nitroprusside and SOD decrease the expression of DNA-PKcs and Ku70/80 of rats cardiomyocytes | |
| Sabol | Next generation sequencing of small RNA in head and neck cancer | |
| Liu | Effect of heat stress on expression of small G protein RhoB in rat livers and human prostate cancer cell line PC-3 cells | |
| Jiang et al. | Expression of 14-3-3 sigma in pancreatic carcinoma and its clinical significance | |
| Xiao | MicroRNA and fundus diseases | |
| Fang et al. | Effects of activation of mitochondrial aldehyde dehydrogenase 2 on MMP-14 and TIMP-4 in high glucose induced rat cardiomyocytes injury | |
| Jiang | Effect of Dracocephalum heterophyllum Benth Flavonoid on Rat Myocardial Cell Hypertrophy Induced by Angiotensin Ⅱ | |
| Dwork et al. | Reduced spinophilin in schizophrenia |